Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02669758 · ClinicalTrials.gov registry record · Phase 3
A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia
A Phase 3 study of Schizophrenia, sponsored by Alkermes.
- Completed
- Registry status
- Phase 3
- Development phase
- 281
- Enrollment target
- 20
- Study locations
NCT02669758 is a Phase 3 study of Schizophrenia that has completed, run by Alkermes. The registered enrollment target is 281 participants, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (29% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT02669758, a Phase 3 study of Schizophrenia, has completed, sponsored by Alkermes.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 281 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to evaluate the long term safety and tolerability of ALKS 3831 in subjects with schizophrenia.
Conditions Studied
Interventions
- DRUG ALKS 3831
Study Locations (20)
Other
- Alkermes Investigational Site - Burgas
- Alkermes Investigational Site - Kazanlak
- Alkermes Investigational Site - Lovech
- Alkermes Investigational Site - Novi Iskar
- Alkermes Investigational Site - Plovdiv
- Alkermes Investigational Site - Sofia
California
- Alkermes Investigational Site - Culver City
- Alkermes Investigational Site - Garden Grove
- Alkermes Investigational Site - Lemon Grove
- Alkermes Investigational Site - Orange
- Alkermes Investigational Site - San Diego
Arkansas
- Alkermes Investigational Site - Little Rock
- Alkermes Investigational Site - Springdale
Florida
- Alkermes Investigational Site - Miami
Illinois
- Alkermes Investigational Site - Chicago
Missouri
- Alkermes Investigational Site - St Louis
Nevada
- Alkermes Investigational Site - Las Vegas
New Jersey
- Alkermes Investigational Site - Marlton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 281 participants |
| Start Date | 2016-01-20 |
| Est. Completion | 2018-06-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02669758
The ClinicalTrials.gov registry entry for NCT02669758 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 281 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (29% higher). The listed sponsor is Alkermes, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which ALKS 3831 is the first listed.
NCT02669758 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, California, Arkansas.
Frequently Asked Questions
What is clinical trial NCT02669758 about?
NCT02669758 is a clinical study titled "A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia". The primary objective of this study is to evaluate the long term safety and tolerability of ALKS 3831 in subjects with schizophrenia.
What is the current status of trial NCT02669758?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 281 participants. The study started on 2016-01-20. Estimated completion is 2018-06-29.
What conditions does trial NCT02669758 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT02669758?
The interventions under investigation include: ALKS 3831 (DRUG).
Who is sponsoring clinical trial NCT02669758?
This trial is sponsored by Alkermes, which has 66 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02669758 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Illinois, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RECRUITING · Phase 3
-
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
RECRUITING · Phase 3
-
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
RECRUITING · Phase 3
-
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
RECRUITING · Phase 3
-
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.